ClinicalTrials.gg
Active, not recruitingNCT06429566Updated Apr 9, 2025

Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers

A Phase 2 interventional study of GB001 recombinant peptide spray low dose group、high dose group and GB001 recombinant peptide spray placebo in Healthy, sponsored by Zhejiang Echon Biopharm Limited. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Zhejiang Echon Biopharm Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2023, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This trial is conducted in China. The purpose is to evaluate the efficacy, Pharmacokinetics (PK) profile, immunogenicity and safety of GB001 recombinant peptide spray in adults with mild recurrent aphthous ulcer.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Zhejiang Echon Biopharm Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. It meets the diagnostic criteria for mild recurrent Aphthous ulcer in the fifth edition of Oral Mucosa published by People's Medical Publishing House in 2020.
  2. 18≤ age ≤65 years old, gender is not limited.
  3. Patients with untreated target ulcer onset ≤48 hours at the time of screening.
  4. VAS score of target ulcer irritation pain ≥3 points, 2mm≤ length diameter of target ulcer ≤10mm.
  5. Subjects and their sexual partners agree to use effective during the study period and for at least 30 days after the study ends.
  6. Sign a written , and be able to comply with the visit and related procedures stipulated in the program.

Exclusion criteria

Exclusion criteria:

  1. The diagnosis was severe aphthous ulcer, herpetic aphthous ulcer, acute herpetic gingivitis stomatitis, traumatic ulcer, cancerous ulcer, tuberculous ulcer, syphilitic ulcer, necrotic salivate metaplasia, Behcet disease and other diseases or drug induced ulcers.
  2. Patients with suppurative tonsillitis or other painful lesions in the mouth, such as pericoronitis, pulpitis, periapical inflammation, etc., affecting the pain score of target ulcer.
  3. Target ulcer is affected by residual root, residual crown, denture, prosthesis, orthodontic device and other stimulating factors in the corresponding parts of the target ulcer.
  4. The ulcer is located in the lingual frenulum, the back wall of the pharynx and other parts, and its size is not easy to measure.
  5. Those who plan to perform other oral treatments during the trial that affect the determination of drug effectiveness and safety.
  6. Smokers > 20 cigarettes/day or betel nut lovers in the past 3 months.
  7. People who have used painkillers or drugs that may affect the efficacy of pain observation within 24 hours before the first administration, such as sedatives, anti-allergy drugs, non-steroidal anti-inflammatory drugs, etc.
  8. Patients who have used antibiotics or antiviral drugs locally or systematically within 1 week before screening.
  9. Patients who had used agents locally within 1 week before screening or systemic immunosuppressive agents within 2 weeks before screening.
  10. Patients with oral local or systemic use of glucocorticosteroids within 4 weeks prior to screening.
  11. Patients who have taken anticholinergic drugs to reduce salivary secretion within 2 weeks prior to screening.
  12. Complicated with severe liver and kidney diseases, or abnormal liver and kidney function tests ( and AST≥ 1.5 times the , SCr > the upper limit of normal).
  13. Patients with severe anemia ( \< 60g/L).
  14. Complicated with severe heart and lung disease, uncontrolled diabetes (fasting blood glucose > 7.0mmol/L or random blood glucose ≥11.1mmol/L), advanced tumors, diseases of the blood and hematopoietic system, or other serious or progressive diseases of the system.
  15. Known or suspected allergic history or serious adverse reactions to the experimental drug and its .
  16. Pregnant or lactating women and those with recent pregnancy plans.
  17. Participants who had participated in other interventional clinical trials within 3 months prior to screening.
  18. Other conditions deemed inappropriate by the investigator for participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    GB001 recombinant peptide spray low dose group

    Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times,The dosage of the group is 0.108mg/spray.

    Drug: GB001 recombinant peptide spray low dose group、high dose group

  • Experimental
    GB001 recombinant peptide spray high dose group

    Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times,The dosage of the group is 0.216mg/spray.

    Drug: GB001 recombinant peptide spray low dose group、high dose group

  • Experimental
    Placebo group

    Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, for 8 days.

    Drug: GB001 recombinant peptide spray placebo

Interventions

  • Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times,The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.

  • DrugGB001 recombinant peptide spray placebo

    Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times

06

What researchers measure

Primary outcomes

  1. Target ulcer healing rate for patients in day 6

    Ulcer healing was defined as disappearance of pain and zeroing of ulcer size. At the screening visit the ulcer area and pain severity of patient to clinical examination will be rated at baseline. The patients will be self-assessment pain severity in vas score sheet every day . And the patients will be re-examined in day 6 to assess the ulcer area by periodontal probe.

    Time frame: Day 6

  2. Subjects self-rated the time it took for irritation pain to disappear

    Time frame: Day 8

Secondary outcomes

  1. Time for target ulcer to heal

    Ulcer healing was defined as disappearance of pain and zeroing of ulcer size.The patients will be self-assessment pain severity in vas score sheet every day . And the patients will be re-examined to assess the ulcer area by periodontal probe.

    Time frame: Day 8

  2. Targeted ulcer healing rate for patients in day 4 and day 8

    Ulcer healing was defined as disappearance of pain and zeroing of ulcer size. At the screening visit the ulcer area and pain severity of patient to clinical examination will be rated at baseline. The patients will be self-assessment pain severity in vas score sheet every day . And the patients will be re-examined in day 4 and day 8 to assess the ulcer area by periodontal probe.

    Time frame: Day 4,Day 8

  3. Changes in target ulcer area relative to baseline

    At the screening visit the ulcer area of patient to clinical examination will be rated at baseline. And the patients will be re-examined in day 4、day 6 and day 8 to assess the ulcer area by periodontal probe.

    Time frame: Day 4,Day 6,Day 8

  4. Self evaluation of pain disappearance rate and relief rate

    Time frame: Day 4,Day 6,Day 8

  5. Pharmacokinetics Characteristics, t½ of GB001 Recombinant Peptide

    Apparent terminal phase half-life

    Time frame: Day 1,Day 4

  6. Pharmacokinetics Characteristics,AUC of GB001 Recombinant Peptide

    Area under the plasma concentration versus time curve

    Time frame: Day 1,Day 4

  7. Pharmacokinetics Characteristics, Cmax of GB001 Recombinant Peptide

    Maximum plasma concentration

    Time frame: Day 1,Day 4

  8. Pharmacokinetics Characteristics, Tmax of GB001 Recombinant Peptide

    Time of maximum plasma concentration

    Time frame: Day 1,Day 4

  9. Immunogenicity(drug resistant antibody (ADA))

    Time frame: Day 1,Day 14,Day 28

  10. Incidence of Adverse Events

    Time frame: First dose to last visit,an average of 1 month.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Dec 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 28, 2024
StartActual
Jul 18, 2023
Primary completionActual
Dec 6, 2023
CompletionEst.
Jul 10, 2026
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06429566
Lead sponsor
Zhejiang Echon Biopharm Limited
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Jul 18, 2023
Primary completion
Dec 6, 2023
Completion
Jul 10, 2026 (estimated)
Last update
Apr 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GB001

Start the discussion